Immuneering (IMRX) Revenue (2020 - 2022)

Immuneering's Revenue history runs 3 years deep, the most recent figure standing at $455.0 for Q4 2022.

• In Q4 2022, Revenue fell 99.76% year-over-year to $455.0; the TTM figure through Sep 2023 stood at $455.0 (down 99.91% YoY), while the FY2022 annual figure was $316952.0, down 84.76% from the prior year.
• Revenue was $455.0 for Q4 2022 at Immuneering, down from $38380.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $748200.0 in Q1 2021 to a low of $455.0 in Q4 2022.
• Historically, Revenue has averaged $384127.1 across 3 years, with a median of $480835.0 in 2020.
• The sharpest annual moves came in 2021 and 2022: Revenue jumped 37.27% in 2021, then plunged 99.76% in 2022.
• A 3-year view of Revenue shows it stood at $665080.0 in 2020, then plunged by 71.49% to $189591.0 in 2021, then slumped by 99.76% to $455.0 in 2022.
• The last three Revenue figures came in at $455.0 (Q4 2022), $38380.0 (Q3 2022), and $94419.0 (Q2 2022), per Business Quant data.